Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% HigherHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% HigherZacks Equity ResearchZacksJanuary 7, 2020ReblogShareTweetShareAcorda Therapeutics, Inc. ACOR was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.68 –$2.75 in the past one-month time frame, witnessed a sharp increase yesterday.Over the last 30 days, the Zacks Consensus Estimate for the current quarter has remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.Acorda Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  Acorda Therapeutics, Inc. PriceAcorda Therapeutics, Inc. PriceMoreAcorda Therapeutics, Inc. price | Acorda Therapeutics, Inc. QuoteA better-ranked stock in the Medical - Biomedical and Genetics industry is Amarin Corporation PLC AMRN, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Is ACOR going up? Or down? Predict to see what others think: Up or DownJust Released: Zacks’ 7 Best Stocks for Today Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.These 7 were selected because of their superior potential for immediate breakout.See these time-sensitive tickers now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Acorda Therapeutics, Inc. (ACOR) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDow Jones Futures Fall Sharply As Coronavirus Stock Market Correction Intensifies; Tesla, Nvidia, Beyond Meat Down LateInvestor's Business Daily'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoAsian markets continue to slump, as Nikkei enters correction territoryMarketWatchStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchThis company is revamping presentation softwareYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance